I expression, and induces successful antitumor immunotherapy. J Exp Med 2006;203:1259–1271.
57Lugade AA, et al: Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 2005;174:7516–7523.
58Matsumura S, et al: Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol 2008;181:3099–3107.
59Aravindan S, et al: Abscopal effect of low-LET gamma-radiation mediated through Rel protein signal transduction in a mouse model of nontargeted radiation response. Cancer Gene Ther 2014;21:54–59.
60Park SS, et al: PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol Res 2015;3:610–619.
61Abuodeh Y, Venkat P, Kim S: Systematic review of case reports on the abscopal effect. Curr Probl Cancer 2016;40:25–37.
62Grass GD, Krishna N, Kim S: The immune mechanisms of abscopal effect in radiation therapy. Curr Probl Cancer 2016;40:10–24.
63Postow MA, et al: Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012;366:925–931.
64Mendes F, et al: The role of immune system exhaustion on cancer cell escape and anti-tumor immune induction after irradiation. Biochim Biophys Acta 2016;1865:168–175.
65Wunderlich R, et al: Low and moderate doses of ionizing radiation up to 2 Gy modulate transmigration and chemotaxis of activated macrophages, provoke an anti-inflammatory cytokine milieu, but do not impact upon viability and phagocytic function. Clin Exp Immunol 2015;179:50–61.
66Twyman-Saint VC, et al: Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015;520:373–377.
67Belcaid Z, et al: Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model. PLoS One 2014;9:e101764.
68Demaria S, et al: Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005;11:728–734.
69Dewan MZ, et al: Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009;15:5379–5388.
70Sharabi AB, et al: Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res 2015;3:345–355.
71Zeng J, et al: Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 2013;86:343–349.
72Grimaldi AM, et al: Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology 2014;3:e28780.
73Kwon ED, et al: Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15:700–712.
74Trump D: Commentary on: “Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.” Urol Oncol 2016;34:249–250.
75Vanpouille-Box C, et al: In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. Vaccine 2015;33:7415–7422.
76Garnett-Benson C, Hodge JW, Gameiro SR: Combination regimens of radiation therapy and therapeutic cancer vaccines: mechanisms and opportunities. Semin Radiat Oncol 2015;25:46–53.
77Mondini M, et al: Synergy of radiotherapy and a cancer vaccine for the treatment of HPV-associated head and neck cancer. Mol Cancer Ther 2015;14:1336–1345.
78Fotin-Mleczek M, et al: mRNA-based vaccines synergize with radiation therapy to eradicate established tumors. Radiat Oncol 2014;9:180.
79Sebastian M, et al: Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer 2014;14:748.
80Lechleider RJ, et al: Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res 2008;14:5284–5291.
81Kamrava M, et al: Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy. Prostate Cancer Prostatic Dis 2012;15:289–295.
82Haji-Fatahaliha M, et al: CAR-modified T-cell therapy for cancer: an updated review. Artif Cells Nanomed Biotechnol 2016;44:1339–1349.
83Lameris R, et al: Bispecific antibody platforms for cancer immunotherapy. Crit Rev Oncol Hematol 2014;92:153–165.
84Weidle UH, Kontermann RE, Brinkmann U: Tumor-antigen-binding bispecific antibodies for cancer treatment. Semin Oncol 2014;41:653–660.
85Cartellieri M, et al: TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity. Oncoimmunology 2013;2:e26770.
86Zegers CM, et al: Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects. Clin Cancer Res 2015;21:1151–1160.
87Rekers NH, et al: Long-lasting antitumor effects provided by radiotherapy combined with the immunocytokine L19-IL2. Oncoimmunology
